Lurasidone in Therapy of Treatment-resistant Ultra-rapid Cycling Bipolar Disorder: Case Report

Lurasidone is an atypical antipsychotic approved for the treatment of schizophrenia and bipolar depression. It seems to have a favorable metabolic profile and low risk of causing adverse interactions. Here we present a case of a 25-year old female patient with treatment-resistant ultra-rapid cycling...

Descripción completa

Detalles Bibliográficos
Autores principales: Siwek, Marcin, Gorostowicz, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean College of Neuropsychopharmacology 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316660/
https://www.ncbi.nlm.nih.gov/pubmed/34294628
http://dx.doi.org/10.9758/cpn.2021.19.3.568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316660/
https://www.ncbi.nlm.nih.gov/pubmed/34294628
http://dx.doi.org/10.9758/cpn.2021.19.3.568

Ejemplares similares